In pan‐cancer immune research, HLA‐DR+CD74+ neutrophils have been identified as alternative antigen‐presenting cells (APCs) in diverse cancer types and can present tumour neoantigens to T cells, thereby reshaping the T‐cell immune pool and enhancing antigen‐specific responses.63 This evidence concerns the gene CD74 and cancer.